Generated June 2026 from current fund data.
Overview
SPYI and SPYT both generate monthly income from S&P 500 exposure through options strategies, but they differ significantly in yield target and tactical approach. SPYI uses a derivative overlay to seek 12.21% annual income while maintaining equity appreciation potential, with $6.20B in assets since its August 2022 launch. SPYT, much newer and smaller at $147M AUM, pursues a more aggressive 20.90% yield by selling daily credit call spreads, accepting tighter upside capture to fund its higher distribution target.
How they differ
The single biggest difference is yield target: SPYT aims for 20.90% annual distributions versus SPYI's 12.21%, a gap SPYT bridges by selling daily 0DTE (zero days to expiration) credit call spreads rather than a broader derivative overlay. That structural choice means SPYT caps upside more explicitly—the spread sales limit stock appreciation in exchange for premium income—while SPYI retains fuller participation in S&P 500 gains. Second, SPYI has a 3.5-year operating history and $6.20B in assets, giving it a longer track record and liquidity cushion, whereas SPYT launched in July 2024 and holds just $147M, making it an unproven strategy at scale. Third, SPYI's beta of 0.69 signals it will lag the broader market in rallies; SPYT's 0.8938 beta sits closer to the index, though its call caps will still dampen gains if the market accelerates.
Who each is best for
SPYI: Fits investors seeking meaningful current income from U.S. large-cap exposure without extreme yield targets, who can tolerate modest equity-like volatility and want to benefit from market upside participation over a multi-year holding period.
SPYT: Designed for investors prioritizing high current distributions and willing to accept capped appreciation and short-term volatility from daily options roll-over, with a higher risk tolerance for new-fund strategy risk and smaller asset bases.
Key risks to know
- NAV erosion potential: Both funds distribute well above long-term S&P 500 total returns (typically 9–10% annually), creating structural pressure to erode net asset value over time. SPYT's 20.90% target makes this risk more acute and will likely require meaningful return-of-capital treatment if markets don't deliver outsized gains.
- Call-cap asymmetry in SPYT: The daily credit spread strategy systematically surrenders upside in strong bull markets. If the S&P 500 rallies sharply, SPYT's capped returns will widen its underperformance relative to SPYI, even though both underperform an unlevered index position.
- New-fund and liquidity risk in SPYT: Launched July 2024 with $147M AUM, SPYT has no multi-year performance record and faces the dual risk of strategy unproof and potential outflows if early distributions disappoint or NAV declines. SPYI's $6.20B buffer and established investor base provide greater structural stability.
- Options volatility and roll risk in SPYT: Rolling 0DTE spreads daily creates operational complexity and sensitivity to sudden implied-volatility spikes, which can compress premium income and force faster NAV declines. SPYI's overlay structure is less granular and may weather IV swings more smoothly.
- Equity market beta drag: Both funds carry meaningful equity beta (0.69 for SPYI, 0.8938 for SPYT), meaning they will participate in broad market downturns, eroding principal even as they generate income—a particularly sharp headwind if yields rest on return-of-capital and distributions don't pause in a recession.
Bottom line
If you prioritize a proven strategy with solid scale and modest upside participation, SPYI's lower yield and established track record stand out; if you're chasing maximum current income and can accept tighter upside caps and unproven execution, SPYT's 20.90% target may appeal—though both funds carry significant risk of NAV erosion if market returns disappoint the high distributions they promise. Past performance does not guarantee future results.
AI-generated analysis for educational purposes only. Verify important details independently; past performance does not guarantee future results.